A disease that affects more than five million people every years has a new defender as reported by CBS News. The promising drug, solanezumab is in the marketplace and it aims to slow the cognitive decline of the brain .
The “experimental” medicine slows Alzheimer’s disease when taken early on, research presented by the Alzheimer’s Association Conference in D.C.
The drug is made by the pharmaceutical company Eli Lilly & Co., is one of only a handful of medications in late-stage testing in the search for a treatment to combat the devastating disease that affects over 5 million Americans.
The medication is designed to target and remove the sticky protein called amyloid that accumulates in the brain of Alzheimer’s patients. To read the entire article, go to CBS News.